Zai Lab (ZLAB) Stock: Buy, Sell, or Hold?
ZLAB - Zai Lab Limited American Depositary Shares
$24.20
-0.88 (-3.51%)
▼
5d:
+7.56%
30d:
-8.37%
90d:
+22.97%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When ZLAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZLAB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ZLAB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZLAB is currently trading at $24.20, which is considered slightly low relative to its 30-day fair value range of $23.96 to $26.00.
Technical Outlook: Technically, ZLAB is in a strong uptrend. Immediate support is located at $22.12, while resistance sits at $25.92. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: ZLAB scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.14 (+36.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZLAB is in a strong uptrend. Immediate support is located at $22.12, while resistance sits at $25.92. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: ZLAB scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.14 (+36.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$23.96 -
$26.00
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 36.9% below Wall St target ($33.14)
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$23.96 -
$26.00
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$22.12
Resistance Level
$25.92
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.47
Wall Street Target
$33.14
(+36.9%)
Revenue Growth (YoY)
-3.3%
Profit Margin
-41.9%
Share & Embed Analysis
Last updated: October 22, 2026 8:47 AM ET
Data refreshes hourly during market hours. Next update: 9:47 AM
Data refreshes hourly during market hours. Next update: 9:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZLAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 47 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 71 BUY |
